EFFECT OF A PARTICLE ENGINEERING PROCESS ON POLYMORPHIC TRANSITION OF PYRAZINAMIDE
Objective: The objective of this work was to investigate the effect of processing on physicochemical properties of spray dried Pyrazinamide.
Methods: Pyrazinamide was spray dried using several spray drying conditions, FTIR, XRD and thermal analysis were undertaken for all samples. A comparison of crystalline/amorphous nature of the starting material as well as processed materials was carried out.
Results: The unprocessed material was a typical crystalline material composed of a mixture of alpha and gamma polymorphic forms of pyrazinamide.
In contrast spray dried materials showed other mixtures of different polymorphs of Â pyrazinamide based on spray drying conditions. In other words, the solid state of spray dried material was dependent on processing parameters (solvent systems, inlet temperature), which may indicate the effect of processing conditions on the solid state of Pyrazinamide.
Conclusion: Processing of Pyrazinamide without excipients gave different polymorphs, according to the solvent mixture used in the spray drying process
2- Byron, P.R. â€œDeterminants of drug and polypeptide bioavailability from aerosols delivered to the lungâ€ Adv. Drug Deliv. Rev. 1990: 5, 107â€“132.
3- Snigdha P, Parthaa N, Laxmidharb M, lalatenduc P. Formulation, â€œevaluation and solid-state thermographic characterization of CFC free beclometasone dipropionate pressurized metered dose inhalationâ€ IJPPS, 2014: 6 (8), 398-403
4- Nolan, L., Tajber, L., McDonald, B., Barham, A., Corrigan, O. I. and Healy, A. M. â€œExcipient-free nanoporous microparticles of budesonide for pulmonary deliveryâ€ European Journal of Pharmaceutical Sciences 2009: 37 (5), 593-602.
5- Pandey, R. and Khuller, G. K. â€œSolid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosisâ€ Tuberculosis (Edinb.) 2005: 85, 227â€“234.
6- Healy AM, Amaro MI, Paluch KJ and Tajber L., â€œDry powders for oral inhalation free of lactose carrier particlesâ€ Advanced Drug Delivery Reviews, 2014: 75, 32-52
7- Corrigan, O. I., â€œThermal analysis of spray dried productsâ€ Therm. Acta, 1995: 248, 245-258.
8- Gad, S, Tajber, L., Corrigan, O. I. and Healy, A. M.., â€œPreparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid stateâ€ Journal of Pharmacy and Pharmacology, 2012: 64, 1264â€“1274
9- Pastrano G and Ghaly S â€œphysicochemical characterization of spray dried formulation containing amorphous drugâ€ IJPPS, 2012: 4 (4), 563-570
10- Thanwar M, Dwivedi D and Gharia A., â€œThe Fundamental Characteristics of Pyrazinamide: A Reviewâ€ J. Chem. & Cheml. Sci. 2014: 4 (2), 110-113
11- European Pharmacopoeia, 5th Edition, (2007)
12- Takaki, Y., Sasada, Y. and Watanabe, T. â€œThe crystal structure of alpha-pyrazinamideâ€ Acta Crystallogr. 1960: 13, 693â€“702.
13- Tamura, C., Sasada, Y. and Kuw1. Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 1992;145:1223-5.
2. Byron PR. Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv Drug Deliv Rev 1990;5:107â€“32.
3. Snigdha P, Parthaa N, Laxmidharb M, lalatenduc P. Formulation, evaluation and solid-state thermographic characterization of CFC free beclometasonedipropionate pressurized metered dose inhalation. Int J Pharm Pharm Sci 2014;6(8):398-403.
4. Nolan L, Tajber L, McDonald B, Barham A, Corrigan OI, Healy AM. Excipient-free nanoporousmicroparticles of budesonide for pulmonary delivery. Eur J Pharm Sci 2009;37(5):593-602.
5. Pandey R, KhullerGK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberc (Edinb) 2005;85:227â€“34.
6. Healy AM, Amaro MI, Paluch KJ, Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Delivery Rev 2014;75:32-52.
7. Corrigan OI. â€œThermal analysis of spray dried productsâ€. Therm Acta 1995;248:245-58.
8. Gad S, Tajber L, Corrigan OI, Healy AM. Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery; impact of ammonium carbonate on morphology, chemical composition and solid state. J Pharm Pharmacol 2012;64:1264â€“74.
9. Pastrano G, Ghaly S. physicochemical characterization of spray dried formulation containing amorphous drug. Int J Pharm Pharm Sci 2012;4(4):563-70.
10. Thanwar M, Dwivedi D, Gharia A. The fundamental characteristics of pyrazinamide: a review. J Chem Chem Sci 2014;4(2):110-3.
11. European Pharmacopoeia, 5th Edition; 2007.
12. Takaki Y, Sasada Y, Watanabe T. The crystal structure of alpha-pyrazinamide. Acta Crystallogr 1960;13:693â€“702.
13. Tamura C, Sasada Y, Kuwano H. Crystallographic data of carboxylic acids and carboxyamides of picoline and pyrazine derivatives. Acta Crystallogr 1961;14:693.
14. Ro G, Sorum H. Crystal and molecular structure of beta-pyrazincarboxamide. Acta Crystall B Stru 1972a;B28:991â€“8.
15. Ro G, Sorum H. Crystal and molecular structure of delta-pyrazincarboxamideâ€ Acta Crystall B Stru B28 1972 b;1677â€“84.
ano, H. â€œCrystallographic data of carboxylic acids and carboxyamides of picoline and pyrazine derivativesâ€ Acta Crystallogr. 1961: 14, 693.
14- Ro, G. and Sorum, H. â€œCrystal and Molecular Structure of Beta-Pyrazincarboxamideâ€ Acta Crystall B Stru B28 (1972 a) 991â€“998.
15- Ro, G. and Sorum, H. â€œCrystal and molecular structure of delta-pyrazincarboxamideâ€ Acta Crystall B Stru B28 (1972 b) 1677â€“1684.